Bristol-Myers, Gilead Team Up
155787
Bristol-Myers Squibb (NYSE: BMY) and Gilead Sciences (Nasdaq: GILD) have taken a much-needed step that should make patients&#39; lives easier even as it improves the companies&#39; results.
723686
FOSTER CITY, Calif. -- Gilead Sciences Inc., a drug research company, said Monday it plans to buy Myogen Inc. for about $2.5 billion in cash, giving Gilead access to Myogen's heart-drug candidates.
66657
FOSTER CITY, Calif.--(BUSINESS WIRE)--Aug. 26, 2004--Fixed-Dose Combination of Viread and Emtriva Recently Approved as Truvada(TM) Gilead Sciences (Nasdaq:GILD) today announced preliminary data from a planned
492501
The biopharmaceutical company removes some uncertainty by teaming up with Novartis.
400965
Medarex's partner advances one of its compounds into later stage clinical testing.
727866
German chemical and drug maker Bayer AG announced Monday it has entered a strategic alliance with the Schering-Plough Corporation that will have the New Jersey-based company market and distribute Bayer&#39;s primary care pharmaceutical products in the United
138698
Another schizophrenia drug from the company shows promise in a clinical trial.
322591
Two competing pharmaceutical companies say they are going to work together to develop the first once-a-day pill to treat HIV - the virus that causes AIDS.
442828
Schering's hepatitis C drug works as well as Roche's.
590148
Schering-Plough Corp. SGP.N is   seriously considering approaching Bristol-Myers Squibb Co.   BMY.N about a possible merger, according to a report in The   Star-Ledger newspaper on Friday.
650860
Johnson & Johnson sets up a collaboration with Isis Pharmaceuticals.
60593
Drug maker Bristol-Myers Squibb Co. and Otsuka Pharmaceutical Co. said Friday that the Food and Drug Administration approved their antipsychotic drug Abilify for the treatment of acute bipolar mania.
333076
Gilead Sciences Inc. , the world's third-biggest biotechnology company, said on Monday it agreed to acquire Myogen Inc.  for $2.5 billion in a surprise transaction that gives Gilead access to Myogen's experimental hypertension drugs.
150142
TRENTON, NJ - Two drug companies announced Monday they will collaborate on developing the first all-in-one, once-a-day pill to treat HIV infection - a long-sought goal that would make it much easier for patients to stick with their medication.
520141
Shares in biotechnology company Gilead Sciences Inc  could climb another 20 percent to 25 percent on strong demand for its existing AIDS and flu drugs as well as from new products in the pipeline, Barron's reported in its July 9 issue.
768183
An experimental drug from Sanofi-Aventis, viewed as pivotal to the newly merged company's future, showed good results in the largest clinical study of the product to date.
727152
New developments are brewing at the pharmaceutical.